0001123292-16-001661.txt : 20160201 0001123292-16-001661.hdr.sgml : 20160201 20160201193926 ACCESSION NUMBER: 0001123292-16-001661 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160121 FILED AS OF DATE: 20160201 DATE AS OF CHANGE: 20160201 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS INC CENTRAL INDEX KEY: 0001175505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260038620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-365-5600 MAIL ADDRESS: STREET 1: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sikorski Robert Steven CENTRAL INDEX KEY: 0001665064 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36070 FILM NUMBER: 161378871 MAIL ADDRESS: STREET 1: C/O FIVE PRIME THERAPEUTICS, INC. STREET 2: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2016-01-21 0 0001175505 FIVE PRIME THERAPEUTICS INC FPRX 0001665064 Sikorski Robert Steven C/O FIVE PRIME THERAPEUTICS, INC. TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 SVP, Global Clinical Develop. Common Stock 101424 D Employee Stock Option (right to buy) 11.92 2024-09-17 Common Stock 80000 D Employee Stock Option (right to buy) 19.25 2025-08-16 Common Stock 20000 D Includes 1,184 shares acquired on November 15, 2015 pursuant to the Company's 2013 Employee Stock Purchase Plan. Includes an aggregate of 100,240 shares of restricted stock, which will vest according to the following schedules: a) 20,000 shares of restricted stock vest according to the following schedule: 50% vests on September 17, 2016 with the remainder vesting on September 17, 2017; b) 5,240 shares of restricted stock vest on January 3, 2017; and c) 75,000 shares of restricted stock vest according to the following schedule: 50% vests on September 1, 2016 with the remainder vesting on March 1, 2017, provided the reporting person remains employed by the Company though each such vesting date. One fourth (1/4th) of the shares underlying the option vested on September 17, 2015, and the remainder of the shares underlying the option vest at a rate of one forty-eighth (1/48th) per month thereafter, provided the reporting person remains employed by the Company through each such date. One forty-eighth (1/48th) of the shares underlying the option vest monthly beginning on September 17, 2015, provided the reporting person remains employed by the Company through each such date. /s/ Francis Sarena, Attorney-in-Fact 2016-02-01 EX-24 2 sikorskipoa.htm POWER OF ATTORNEY

Power of Attorney
The undersigned, hereby constitutes and appoints Marc Belsky and Francis Sarena, and each of them, for so long as such person is an officer of Five Prime Therapeutics, Inc., a Delaware corporation ("FivePrime"), and Laura Berezin, for so long as she is a partner of a law firm representing FivePrime, the undersigned's true and lawful attorney-in-fact, with full power of substitution and resubstitution, each with the power to act alone for the undersigned and in the undersigned's name, place and stead, to:
1.
Complete and execute Forms 3, 4 and 5 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and other forms and all amendments thereto on the undersigned's behalf as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Exchange Act and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's beneficial ownership of securities of FivePrime or changes in such beneficial ownership; and
2.
Do all acts necessary in order to file such forms and amendments with the Securities and Exchange Commission, any securities exchange or national association, FivePrime and such other persons or agencies as the attorney-in-fact shall deem appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is FivePrime assuming, any of the undersigned's responsibilities to comply with or liability under Section 16 of the Exchange Act or any rules and regulations promulgated thereunder or any successor laws and regulations.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's beneficial ownership of securities of FivePrime or changes in such beneficial ownership, unless earlier revoked by the undersigned in a signed writing delivered to FivePrime and to the foregoing attorneys-in-fact.
The undersigned has executed this Power of Attorney as of January 21, 2016.
 
 
 
/s/ Robert S. Sikorski
 
 
 
 
Robert S. Sikorski